A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.
Also called NCT07357675
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 300 participants
- Sponsor
- EBI Anti Sepsis BV
- Registry
-
NCT07357675
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Belgium, Netherlands, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT07357675. Randomized; triple masking; primary purpose treatment. Start 2026-10-29 (actual); primary completion 2027-10-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.
- Acronym
- EasyBoost
- Condition
- Coronary Artery Bypass Graft Surgery(CABG (coronary artery bypass grafting))
- Intervention (Drug)
- EA-230 90mg/kg/hour
- Intervention (Drug)
- Placebo
- Lead sponsor
- EBI Anti Sepsis BV
- Collaborator
- CR2O B.V.
Record details
- Record id
cardio:ct-nct07357675- Content hash
2791a207eda0ca40f1b106d525fd6c9756deb9315a1dc7f4b13de8eda68ec60c